Institute of Health Service & Transfusion Medicine, Academy of Military Medical Sciences, Hebei 100850, PR China.
Department of Blood Transfusion, The 988 hospital of PLA, Henan 450042, PR China.
Nanomedicine (Lond). 2019 Oct;14(19):2519-2533. doi: 10.2217/nnm-2019-0154. Epub 2019 Jul 18.
To explore the potential therapeutic effect of yttrium oxide nanoparticles (YO NPs) on fulminant hepatic failure. RAW264.7 cells and a lipopolysaccharide/D-galactosamine-induced hepatic failure murine model were used to assess the effects of YO NPs. YO NPs exhibited anti-inflammatory activity by scavenging cellular reactive oxygen species and dampening reactive oxygen species-mediated NF-κB activation . A single intraperitoneal administration of YO NPs (30 mg/kg) enhanced hepatic antioxidant status and reduced oxidative stress and inflammatory response in lipopolysaccharide/galactosamine-induced mice. YO NPs also attenuated hepatic NF-κB activation, cell apoptosis and liver injury. YO NP administration could be used as a novel therapeutic strategy for treating fulminant hepatic failure and oxidative stress-related diseases.
探讨氧化钇纳米粒子 (YO NPs) 对暴发性肝衰竭的潜在治疗作用。使用 RAW264.7 细胞和脂多糖/半乳糖胺诱导的肝衰竭小鼠模型来评估 YO NPs 的作用。YO NPs 通过清除细胞内活性氧物质和抑制活性氧介导的 NF-κB 激活来发挥抗炎作用。单次腹腔注射 YO NPs（30mg/kg）可增强肝抗氧化状态，减轻脂多糖/半乳糖胺诱导的小鼠的氧化应激和炎症反应。YO NPs 还可减轻肝 NF-κB 激活、细胞凋亡和肝损伤。YO NP 给药可作为治疗暴发性肝衰竭和氧化应激相关疾病的新治疗策略。
